Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b/3 Study of Clesrovimab (MK-1654) for RSV Prevention in Healthy Preterm and Full-Term Infants
jRCT2051210019Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Clesrovimab (MK-1654) with Placebo (2 arms). Started Jun 2021; status: completed.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2051210019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210019.